1. Pink Sheet
  2. >>Pathways & Standards

NASH Accelerated Approval: US FDA Remains Confident In Pathway For Liver Disease

 
• By Michael McCaughan

A two-day workshop on potential biomarkers in NASH provided a forum for US FDA officials to offer implicit reassurance to drug developers: the agency stands behind its guidance on Accelerated Approval for the liver disease, despite the rejection of the first application seeking to use that approach.

MASH-NASH
NASH (non-alcoholic steatohepatitis) is now also known as MASH (metabolic dysfunction associated steatohepatitis). • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

US FDA review officials believe the experience with post-marketing cardiovascular outcomes trials in diabetes is a strong indication that it will be possible to complete rigorous, long-term confirmatory studies for drugs that receive Accelerated Approval to treat NASH.

“While there are clear challenges to feasibly and reliably carrying out these clinical benefit trials after an Accelerated Approval, I...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 
• By Neena Brizmohun

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

US FDA Acting Drug Center Chief Corrigan-Curay Retiring, Senior Staff Remake Continues

 
• By Derrick Gingery

The news coincides with rumors that Commissioner Martin Makary soon will name a new Center for Drug Evaluation and Research director.

EU Pharma Reform: Lawyers Unpack Diverging Visions For Innovation

 
• By Eliza Slawther

There are now three draft versions of the legislative text that will overhaul the framework governing pharmaceuticals in the EU. Lawyers explain how the approaches proposed by the European Commission, European Parliament and Council of the EU differ and highlight implications for industry.